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Objective: To evaluate the available literature regarding Upper Airway Resistance Syn-
drome (UARS) treatment. Methods: Keywords “Upper Airway Resistance Syndrome,”
“Sleep-related Breathing Disorder treatment,” “Obstructive Sleep Apnea treatment” and
“ﬂow limitation and sleep” were used in main databases. Results: We found 27 articles
describing UARS treatment. Nasal continuous positive airway pressure (CPAP) has been the
mainstay therapy prescribed but with limited effectiveness. Studies about surgical treatments
had methodological limitations. Oral appliances seem to be effective but their efﬁcacy is not yet
established. Conclusion: Randomized controlled trials with larger numbers of patients and long-
term follow-up are important to establish UARS treatment options.
& 2015 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Upper Airway Resistance Syndrome (UARS) was ﬁrst named
by Guilleminault in 1993 [1] while investigating cases of excessive
daytime sleepiness with no identiﬁed cause in adults. However,
the respiratory pattern of increased upper airway resistance was
previously identiﬁed in pre-pubertal children under the label
“sleep-related respiratory resistive load” [2].ep. Production and Hosti
licenses/by-nc-nd/4.0/).
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an Association of Sleep.Since this ﬁrst description, many authors have attempted
to describe the clinical and polysomnographic features of
UARS patients based on their experience, to ﬁnd a deﬁnitive
way to diagnose and ﬁnally treat them. In particular, during
the last twenty years, the deﬁnition of UARS has varied
(Table 1). Currently, UARS is subsumed under the diagnosis
of Obstructive Sleep Apnea Syndrome (OSAS) by the American
Academy of Sleep Medicine (AASM) (Berry AASM 2012) [3].ng by Elsevier B.V. This is an open access article under the CC BY-
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Table 1 – UARS deﬁnitions.
Authors Clinical
criteria
Polysomnographic criteria
Kristo et al., 2005
[47]
Excessive
daytime
sleepiness
(ESS 410)
Pesr- 12 cm H2O AHIo5/hour, Arousal IndexZ10/hour,
RERAZ5/hour
Guilleminault
et al. [7]
Excessive
daytime
sleepiness or
fatigue
Pes and ﬂow limitation by nasal cannula AHIo5/hour, RDI45/hour (RERA), Oxygen
saturation492%
Loube et al., 2009
[48]
Excessive
daytime
sleepiness
Inductance plethysmogrhaphy Pesr- 12
cm H2O
AHIo5/hour and RERAZ10/hour
Stoohs et al., 2009
[49]
Excessive
daytime
sleepiness or
fatigue
Flow limitation by nasal cannula AHIo5/hour and presence of RERA
Pépin et al., 2012
[6]
Excessive
daytime
sleepiness
Pes, ﬂow limitation by nasal cannula RERA as more than 50% of respiratory events
ESS: Epworth Sleepiness Scale, Pes: Esophageal pressure, AHI: Apnea / Hypopnea Index, RERA: Respiratory Event-Related Arousal,
RDI: Respiratory Disturbance Index
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believe that UARS is part of a continuum between primary
snoring and OSAS whereas others believe that it is a distinct
syndrome from OSAS. Some authors support that both UARS
and OSAS have the same symptoms and as their pathophy-
siology do not signiﬁcantly differ from each other, UARS
is not a distinct disease [4,5]. Nevertheless, other authors
believe that UARS patients present different features than
other Sleep related Breathing Disorder (SRBD) [6,7,8]. The
most frequent symptoms are excessive daytime sleepiness,
fatigue and sleep fragmentation. However, UARS patients
also present signiﬁcantly more often with sleep-onset and
sleep-maintenance insomnia, postural hypotension, head-
aches, gastroesophageal reﬂux, irritable bowel syndrome,
anxiety and alpha-delta sleep [9,10,11]. The proportion of
women with UARS is also signiﬁcantly higher than for OSAS
[12]. Besides having some different clinical presentation, it
has been suggested that UARS and OSAS differ from each
other in terms of their sleep EEG and autonomic nervous
system responses. Some authors believe that UARS patients
have an increase in alpha rhythm and an over-activation of
the autonomic nervous system [13].
UARS diagnosis is suspected in individuals with com-
plaints of excessive daytime sleepiness or daytime tiredness,
no OSAS and a polysomnographic study with respiratory
parameters indicative of increased upper airway resistance,
such as, ﬂow limitation during sleep. They present arousals
associated with increase in respiratory effort leading to sleep
fragmentation and excessive daytime sleepiness. The poly-
somnographic studies of these patients also showed
sequences of breaths with ﬂow limitation, which were inter-
rupted by abrupt arousals. Arousals were deﬁned using
American Sleep Disorders Center-American Academy of
Sleep Medicine (AASM) [14,15] conventional criteria but were
also described using the cyclic alternative pattern-CAP-atlas,
[16] including the shorter duration arousals associated withabnormal increases of “Phase A2” and “Phase A3” of the CAP
scoring system and with RERA [17]. The arousals associated
with ﬂow limitations were described as “respiratory event
related arousals” (RERA) by AASM [14,15]. The polysomno-
graphy (PSG) pattern of “ﬂow limitation,” introduced in 1991
[18] was further investigated and deﬁned particularly in New
York [19,20] as a sign of increased upper airway resistance to
airﬂow.
Untreated UARS individuals can present low quality of life
and cardiovascular consequences. Sleep and daytime symp-
toms, such as fatigue, insomnia and depressive mood, in
untreated UARS usually increase over time [7]. The syn-
drome's characteristic esophagic pressure (Pes) negativity
can cause a diastolic leftward shift of the interventricular
heart septum and a consequent ventricular “collapse”. [21]
The longlasting ﬂow limitation episodes can induce a small
increase in end-tidal carbon dioxide (PetCO2) that can stimu-
late the sympathetic nervous system activity. This could
cause hypertension, and cardiovascular and metabolic con-
sequences. [6] Even an increase in inﬂammatory markers can
happen in non-treated UARS individuals. [22]
In order to avoid the consequences mentioned above, a
proper treatment should be offered to UARS patients. There
are some treatment studies available in the literature, but
most of these are case reports and case series. Nasal con-
tinuous positive airway pressure (CPAP) is one treatment
option that has been evaluated as a therapy for UARS, and
the available studies demonstrated that it can improve
different aspects of the condition. CPAP treatment was asso-
ciated with signiﬁcant improvements in the excessive day-
time sleepiness, numbers of transient arousals and abnormal
upper airway resistance.1 Other types of treatments evalu-
ated included oral appliances, nasal and palatal surgeries and
maxillomandibular advancement. Long-term studies to eval-
uate treatment response will be helpful to better deﬁne
this SBD.
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describing UARS treatment.2. Methods
A systematic search of articles covering 1982 to date using
Medline (via PubMed), Scielo, Lilacs, The Cochrane Library
and Web of Science was conducted to identify published
articles regarding UARS treatment. The search terms used
were: “Upper Airway Resistance Syndrome”, “Upper Airway
Resistance Syndrome AND treatment”, “Sleep-related Breath-
ing Disorder AND treatment”, “Obstructive Sleep Apnea
AND treatment” and “ﬂow limitation AND sleep”. “Sleep
apnea, obstructive” is a MeSH (Medical Subject Heading) in
PubMed, and we used the subheadings “diet therapy,” “drug
therapy,” “surgery” and “therapy” to improve the search.
Articles describing either adult or pediatric populations were
included. Only articles published in English were considered.
The literature search and the screenings of headings and
abstracts were made by two different authors (LG and LP)
independently. Both of them read all 27 fulltext articles that
were assessed for eligibility. If consensus was not achieved,
ST was included for a ﬁnal decision.3. Results
We found 457 articles in PubMed and 909 articles in Scielo,
Cochrane, Bireme, Lilacs and Web of Science when the key-
words “Upper Airway Resistance Syndrome” were used. Only
15 articles focused on UARS treatment, and all the articles
included in Scielo, Cochrane, Bireme, Lilacs and Web of
Science were also included in PubMed. We considered only
once the articles that were identiﬁed twice because they were
listed in two different sources. We also found 10 UARS
systematic reviews that mentioned the syndrome's treat-
ment along the article. Of the 349 articles found in PubMed
using the keyword “Sleep-related Breathing Disorder AND
treatment,” none of them were about UARS treatment, and of
the 493 articles found in Scielo, Cochrane, Bireme, Lilacs and
Web of Science only 1 was about UARS treatment. In PubMed,
5051 articles were found using “Obstructive Sleep Apnea AND
treatment” (with its respective MeSH) as the keyword, but
only 1 was about UARS treatment. Of the 9147 articles found
in Scielo, Cochrane, Bireme, Lilacs and Web of Science when
the keyword “Obstructive Sleep Apnea AND treatment” was
used, none focused on UARS treatments. Of the 222 articles
found in PubMed and from the 678 articles in Scielo,
Cochrane, Bireme, Lilacs and Web of Science using the key-
words “ﬂow limitation AND sleep,” none described UARS
treatments.
Seventeen (17) articles (Table 2) and ten (10) reviews were
initially evaluated (Fig. 1). A summary of the original articles
evaluated with year and journal of publication, study design,
number and characteristics of the patients and conclusions
are described in Table 2. The reports consisted mainly of case
reports and case series. The main ﬁndings are discussed below.
From the 17 articles analyzed, 4 were about CPAP treat-
ment [1,23,24,25], 1 about drug treatment [26], 1 about CPAPand surgery [27], 1 was about rapid palatal expansion [28], 4
about surgery [22–32], 5 about oral device treatment [33–37]
and 1 about external nasal device [38]. The deﬁnition of UARS
also varied. Seven studies considered polysomnographic
aspects associated to symptoms such as excessive daytime
sleepiness, fatigue or snoring to diagnose UARS. Other stu-
dies only considered objective parameters from sleep study.
The polysomnographic parameters considered were AHI
less than 5–15 events/hour (10 studies) [24,25,27,28,31,32,34,
35,37,38], RDIo5–10 events/hour (3 studies) [29,30,33], RDI45
events/hour (2 studies) [31,35], Pes more negative than
10 or 20 mmH2O (8 studies) [1,23,24,27,29,30,33,35], total
arousal index (TAI)45–15 events/hour (7 studies) [1,24,25,33,
34,35,38], the presence of excessive daytime sleepiness or
fatigue or snoring (9 studies) [22,25,26,29,30,32,33,36,38] and
presence of RERA or ﬂow limitation (3 studies). [25,27,28]
In summary, therapeutic data about UARS treatment are
few and consists of CPAP, oral device, surgery and external
nasal device. There are no UARS cohorts with long-term
treatment and follow-up available. Most studies about UARS
treatment are observational and case reports. There were
only two randomized double-blind, placebo-controlled stu-
dies published. Indeed, most studies have an inadequate
methodology with a small number of patients and without
precise sample estimation.4. Discussion
Mild SBD criteria and events identiﬁcation have been subject
of discussion. The diagnosis of UARS is still controversial.
Currently, UARS is considered part of Obstructive Sleep
Apnea Syndrome (OSAS) by the AASM. OSAS is deﬁned as
the presence of more than 5 obstructive events per hour
associated with symptoms or more than 15 events per hour
independent of symptoms. Currently, there is no data with
outcomes available deﬁning the cut off limit for RERAs and
Respiratory Disturbance Index (RDI) in SBD patients, as well
as, on healthy individuals. Respiratory index, such as, apnea/
hypopnea index (AHI) and RDI has been used with different
deﬁnitions and considering different respiratory events.
There are still several issues that need to be better deﬁned
and established regarding UARS, however, most authors
today agree that sleep breathing disorders cannot be limited
just to OSAS criteria.
CPAP is the UARS treatment modality better investigated.
[1,23,24] One month of therapeutic trial with nasal CPAP can
signiﬁcantly change objective polysomnographic parameters
[1] and subjective complaints. [1,23,24] CPAP treatment was
associated to decrease in transient arousals, increase in
percentage of NREM stages 3 and 4 and the sleep latency at
MSLT. [1] Subjective daytime sleepiness, fatigue [1,23] and
snoring [24] also can improve after CPAP treatment. Never-
theless, in some studies there were patients that did not have
their excessive daytime sleepiness and fatigue decreased
after CPAP treatment [24]. Consequently, these patients did
not comply with CPAP due to the lack of beneﬁcial effects [24].
Even though CPAP may be an effective treatment for UARS,
the compliance is low in this patient population. Also, in
follow up studies a signiﬁcant part of patients did not use the
Table 2 – Articles included in the review.
Publications Patients Conclusion
Case reports
Miller P et al. J Med Case
Rep [28]
1 patient with UARS Rapid palatal expansion may improve resistant adolescent
depression with UARS
Venkat et al. Indian J Dent
Res [36]
5 patients with UARS Mandibular advancement device was better than four novel
prosthodontic methods for UARS
Yoshida. J Prosthet Dent [37] 32 patients with UARS Oral device therapy was effective in reducing objective and
subjective daytime sleepiness
Guerreiro et al. Sleep
Breath; 2001 [35]
1 patient with UARS with
nocturnal asthma
Oral appliance can help control nocturnal asthma in patients with
UARS and asthma
Ong et al. Ann Acad Med
[23] Singapore; 2000
2 patients with UARS Nasal CPAP improve excessive daytime sleepiness (Epworth)
Rose et al. Sleep Breath [34] 1 patient with UARS An oral appliance improved daytime sleepiness in UARS
Loube et al. Sleep Breath
[33]
1 patient with UARS An oral appliance treatment decreased daytime sleepiness, snoring,
transient arousals and Pes
Non-randomized studies
Tschopp et al. Eur Arch
Otorhinolaryngol [32]
35 patients with UARS and
109 with OSAS
After septoplasty, palatal surgery and hyoid suspension,
preoperative AHI and tonsillectomy had a highly signiﬁcant
inﬂuence on the postoperative AHI
Lewis and Ducic. J
Otolaryngol. [31]
4 UARS and 13 OSAS After genioglossus muscle advancement, snoring and
hypersomnolence were improved
Guilleminault et al. J
Psychosom Res, 2002 [27]
62 patients with UARS x
68 chronic insomniacs
Treating the underlying breathing disorder with CPAP or nasal
turbinectomy can improve complaints of post-menopausalwomen
with chronic insomnia and UARS
Edwards et al. Am J
RespirCrit Care Med [25]
11 women with severe
preeclampsia
AutoCpap eliminated ﬂow limitation
Watanabe et al. Psychiatry
ClinNeurosci [24]
14 patients with UARS Nasal CPAP and hormone replacement therapy improved snoring
Utley, Laryngoscope [30] 11 patients with UARS Improvement of subjective daytime sleepiness after LAUP
Newman et al.
Laryngoscope, [29]
9 patients with UARS Nasal and palatal surgeries decreased subjective daytime sleepiness
and snoring
Guilleminault et al. Chest
[1]
15 patients with UARS CPAP eliminated the daytime sleepiness, the transient arousals and
abnormal upper airway resistance
Randomized double-blind studies
Bahammam et al. Sleep [38] 18 patients with UARS External nasal dilation reduced stage 1 sleep and desaturation time
Lofaso. EurRespir J [26] 8 patients with UARS Zolpiclone 7.5 mg improved sleep efﬁciency index and objective
sleepiness (MSLT)
UARS: Upper Airway Resistance Syndrome, CPAP: Continuous Positive Airway Pressure, OSAS: Obstructive Sleep Apnea Syndrome, MSLT:
Multiple Sleep Latency Test, LAUP: Laser-assisted Uvuloplasty, Pes: esophageal pressure
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insurance companies to cover its prescriptions, on the basis
that according to their policies, UARS did not meet the criteria
for a CPAP prescription [7].
Auto-CPAP was indicated to treat pregnant women with
severe preeclampsia and ﬂow limitation [25]. The mean
overnight blood pressure was markedly reduced during the
night of treatment with nasal CPAP when compared with the
nontreatment night. The authors suggest that nasal CPAP
may be considered as a therapy to improve blood pressure
control in women with severe preeclampsia and ﬂow limitation.
Medications that decrease sleep fragmentation could be
also helpful for UARS patients. 7.5 mg Zopiclone during 1
week produced signiﬁcant improvements in the sleep efﬁ-
ciency index and average sleep latency in MSLT [26]. Never-
theless, it had no effect on respiratory parameters during
sleep and daytime sleepiness in patients with UARS. Despite
some improvements demonstrated objectively in the poly-
somnography, Zopiclone use did not decrease UARS symp-
toms. It was concluded that medications that consolidatesleep could be an adjuvant medicine used during the main
treatment of UARS patients.
Sleep fragmentation persists in many patients with
insomnia despite an adequate insomnia treatment. The sleep
fragmentation associated with UARS can cause daytime
fatigue and enhance anxiety, factors that can increase the
difﬁculty in treating chronic insomnia. Postmenopausal
women with chronic insomnia and UARS had their daytime
fatigue decreased after nasal treatment (nasal radio-frequ-
ency ablation of turbinate or septoplasty with turbinectomy)
and nasal CPAP-treatment [27]. This study reinforce
the idea that SBD should be investigated in patients with
chronic insomnia to guarantee an adequate insomnia treat-
ment result.
Psychiatric patients may also present SDB. A case report
about a young man with treatment-resistant depression and
with sleep symptoms (insomnia, fatigue and daytime sleepi-
ness) was investigated for SDB [28]. As his psychiatric symp-
toms were not well controlled despite an adequate medical
treatment and he had sleep complaints he underwent a sleep
Records on adjacent 
topics excluded
(n =5947)
Records on adjacent 
topics excluded
(n = 86)
Additional records 
identified through 
other sources 
(n = 0)
Studies included in 
qualitative synthesis
(n = 27)
Full text articles 
assessed for eligibility
(n = 46)
Abstracts screened
(n = 132)
Records after duplicates 
removed
(n = 6079)
Records identified 
through database 
searching 
(n = 17306)
Full text articles 
excluded with reasons:
- Articles not published 
in English
(n = 13)
- Records on adjacent 
topics
(n = 6)
Fig. 1 – Flow diagram for identiﬁcation of articles that were
evaluated, excluded and included in the review.
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palatal expansion and during the two-year follow-up
remained free from symptoms of depression, anxiety, sleepi-
ness or fatigue in the absence of any psychotropic medica-
tion, although there were no statistically signiﬁcant changes
in the polysomnographic parameters. This article reinforces
the idea that a sleep study should be included and SBD
should be investigated in psychiatric patients who have
persistent sleep complaints and whose psychiatric symptoms
are not controlled despite an adequate medical treatment.
Upper airway surgeries have also been evaluated as UARS
treatment option. Craniofacial abnormalities that may
increase upper airway resistance are often present in UARS.
Dental malocclusion and elevated ogival hard palate as well
as a narrow posterior airway space can be frequent ﬁndings
in upper airway examination [39]. Surgical treatment were
studied as an option for patients who cannot tolerate or are
unwilling to adhere to CPAP therapy [29]. Some authors
studied UARS patients that preferred surgery (such as septo-
plasty, turbinate reduction, laser-assisted uvuloplasty – LAUP,
uvulopalatopharyngoplasty, genioglossus bone advance-
ment, mandibular osteotomy with tongue advancement and
hyoid miotomy with suspension) rather than CPAP [29–31].
Sleep studies were performed from 3 to 6 months after
treatment [29–31]. The only outcome evaluated in these
studies were subjective sleepiness [29–31] and snoring [30–
31] and the follow-up was not long enough to consider
surgery a long-term effective management for this group of
patients.
Many authors agreed that procedures should address
anatomical regions that cause upper airway obstruction and
that UARS treatment consists of approaching the causes ofthe upper airway anatomical problems such as treatment of
nasal allergies, usage of palatal soft-tissue surgeries, orthog-
natic surgery or use of dental devices [6,40,41,42,43,44]. Some
authors had even tried to formulate a statistical model for
postoperative AHI after multilevel surgery in UARS patients
[32]. It was concluded that tonsillectomy had a highly
signiﬁcant inﬂuence on postoperative AHI.
Concluding, few studies evaluating surgical treatment for
UARS are available. Most studies about surgery treatment
only consider subjective outcomes and the number of
patients has been too low to lead to conclusive results. Many
methodological problems in published literature did not
allow a proper analysis [45,46]. Randomized prospective
protocols of surgical procedures should be conducted.
Another treatment option for SDB is the use of oral
devices. Oral devices move the mandible and tongue forward
in order to minimize the oropharyngeal obstruction. Patients
with UARS present a narrow posterior airway space behind
the base of the tongue. Oral devices increase upper airway
dimensions and are often indicated for mild SBD. There
are some case reports [33–36] and a prospective study [39]
published about oral device as UARS treatment. Some
authors noticed polysomnographic differences, such as a
decrease in the total arousal index (TAI) [33,34,37], a less
negative mean Pes [33,34], an improvement in sleep efﬁciency
[37] and lower oxygen saturation [37]. A signiﬁcant increase in
the mean sleep latency in the MSLT [34,35] and an absence of
sleep during the Maintenance of Wakefulness Test (MWT)
was also observed [34]. Oral appliance also decreased sub-
jective daytime sleepiness [33,37] and snoring [33]. Another
study report a case of oral appliance indicated for an
asthmatic patient with UARS that had poorly controlled
asthma symptoms despite high-doses steroids [35]. The
post-treatment polysomnography showed normalization of
the Pes and decrease in the TAI. Even the asthma symptoms
were better controlled and lower doses of drugs were
required after the oral device treatment.
The side effects of oral devices observed (excessive saliva-
tion and transient tooth discomfort) were minor and toler-
able, and no major complications were reported [37].
Objective and subjective aspects of the treatment response
were evaluated during a longer follow up. The results demon-
strated that oral appliance was effective in decreasing sleep
fragmentation and objective and subjective daytime sleepi-
ness and was also well tolerated.
Other types of oral devices besides the mandibular
advancement device were also published as case reports
but the study did not report clinical or polysomnographic
changes pre- and post-treatment [36].
Nasal obstruction is another cause of ﬂow limitation and
can lead to occlusion of the pharyngeal airway. The decrease
in nasal resistance might also reduce the inspiratory effort.
A double-blind, randomized, controlled trial with a cross-over
design study was performed to evaluate the effect of external
nasal dilatation in UARS patients [38]. The external nasal
dilator signiﬁcantly increased nasal cross-sectional area,
reduced stage 1 sleep and decreased desaturation time when
comparing to the placebo treatment. These were the only
changes observed after treatment. There were no signiﬁcant
effects on the MSLT, AHI or TAI or on the clinical complaints.
S l e e p S c i e n c e 8 ( 2 0 1 5 ) 4 2 – 4 8 47The absence of signiﬁcant clinical changes after treatment,
despite the polysomnographic differences, demonstrated
that this device, currently, cannot be recommended for the
treatment of UARS. Future studies with a larger number of
patients and with a longer follow-up should be conducted to
better analyze this device's effects on UARS patients.5. Conclusion
Currently, there are few well designed studies available of
UARS treatment, CPAP has been the primary therapy pre-
scribed, but its effectiveness has been limited because of low
patient compliance and there are no randomized controlled
trials evaluating this type of treatment in UARS patients. The
available studies that have evaluated surgical treatments of
UARS patients have methodological limitations and low
numbers of patients evaluated. Oral appliances seem to be
an effective option, but only case reports and small case
series have been reported, and the efﬁcacy of these devices is
not yet established for this group of patients. Randomized
controlled trials comparing different modalities of treatment
with larger numbers of patients and including long-term
follow-up are important to better deﬁne and establish treat-
ment options in UARS patients.Conﬂict of interest
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